Cogent Biosciences (COGT) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed Cogent Biosciences (COGT) over the past year, gaining 136.0% versus a gain of 93.1%. Over five years, COGT leads with a +225.5% price change compared with +63.4% for PGEN. Cogent Biosciences is the larger company by market cap ($5.30 billion vs $2.79 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | PGEN |
|---|---|---|
| Share price | $30.53 | $7.78 |
| Market cap | $5.30B | $2.79B |
| 1-day change | +1.50% | +2.37% |
| YTD return | -15.32% | +81.82% |
| 1-year return | +93.07% | +136.02% |
| 5-year return | +225.54% | +63.44% |
| EPS (TTM) | $-2.16 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | $-328.94M | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $43.73 | $8.98 |
| 52-week low | $13.78 | $2.99 |
| Distance from 52-week high | -30.19% | -13.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +82.84% | +75.45% |
| Average volume | 1.90M | 5.03M |
| Shares outstanding | 173.52M | 358.04M |
| Employees | 258 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed COGT by 43.0 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
COGT vs PGEN FAQ
Which is bigger, Cogent Biosciences or Precigen?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.30B compared with $2.79B for Precigen (PGEN).
Which stock has performed better over the past year, COGT or PGEN?
PGEN returned +136.02% over the past 12 months, compared with +93.07% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.